Commonwealth of Pennsylvania Public School Empls Retrmt SYS Has $692,000 Position in Emergent Biosolutions Inc (EBS)
Commonwealth of Pennsylvania Public School Empls Retrmt SYS increased its position in shares of Emergent Biosolutions Inc (NYSE:EBS) by 40.4% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 10,508 shares of the biopharmaceutical company’s stock after buying an additional 3,025 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS’s holdings in Emergent Biosolutions were worth $692,000 at the end of the most recent reporting period.
Other institutional investors have also recently added to or reduced their stakes in the company. Thompson Siegel & Walmsley LLC purchased a new stake in Emergent Biosolutions during the 2nd quarter worth $202,000. Parametrica Management Ltd purchased a new stake in Emergent Biosolutions during the 3rd quarter worth $223,000. Family Firm Inc. purchased a new stake in Emergent Biosolutions during the 3rd quarter worth $225,000. Intrust Bank NA purchased a new stake in Emergent Biosolutions during the 2nd quarter worth $234,000. Finally, Sun Life Financial INC purchased a new stake in Emergent Biosolutions during the 2nd quarter worth $234,000. 81.39% of the stock is currently owned by hedge funds and other institutional investors.
EBS opened at $68.65 on Thursday. The stock has a market capitalization of $3.71 billion, a PE ratio of 36.13, a P/E/G ratio of 1.85 and a beta of 1.26. Emergent Biosolutions Inc has a 1-year low of $41.59 and a 1-year high of $73.89. The company has a quick ratio of 4.29, a current ratio of 5.52 and a debt-to-equity ratio of 0.01.
In related news, Director Sue Bailey sold 17,717 shares of the business’s stock in a transaction dated Tuesday, November 27th. The shares were sold at an average price of $69.62, for a total transaction of $1,233,457.54. Following the completion of the sale, the director now owns 57,216 shares of the company’s stock, valued at approximately $3,983,377.92. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Daniel Abdun-Nabi sold 1,319 shares of the business’s stock in a transaction dated Monday, September 17th. The shares were sold at an average price of $65.00, for a total transaction of $85,735.00. Following the sale, the chief executive officer now directly owns 194,787 shares of the company’s stock, valued at approximately $12,661,155. The disclosure for this sale can be found here. Insiders sold a total of 163,678 shares of company stock valued at $11,030,898 in the last three months. Insiders own 13.40% of the company’s stock.
EBS has been the topic of several analyst reports. Goldman Sachs Group raised shares of Emergent Biosolutions from a “neutral” rating to a “buy” rating and lifted their price target for the stock from $60.00 to $75.00 in a research note on Friday, November 2nd. Zacks Investment Research reissued a “hold” rating on shares of Emergent Biosolutions in a research report on Tuesday, November 13th. Wells Fargo & Co set a $61.00 target price on shares of Emergent Biosolutions and gave the stock a “hold” rating in a research report on Friday, August 10th. Cantor Fitzgerald boosted their target price on shares of Emergent Biosolutions from $68.00 to $75.00 and gave the stock an “overweight” rating in a research report on Friday, November 2nd. Finally, Cowen reissued a “hold” rating and issued a $64.00 target price on shares of Emergent Biosolutions in a research report on Tuesday, November 20th. Three equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $68.13.
Emergent Biosolutions Profile
Emergent BioSolutions Inc focuses on the development, manufacture, and commercialization of medical countermeasures that address public health threats. Its products address public health threats primarily chemical, biological, radiological, nuclear, and explosive-related threats, as well as infectious diseases.
Featured Story: Coverage Ratio
Want to see what other hedge funds are holding EBS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Emergent Biosolutions Inc (NYSE:EBS).
Receive News & Ratings for Emergent Biosolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions and related companies with MarketBeat.com's FREE daily email newsletter.